Approval for a new rf generator.  The device, as modified, will be marketed under the trade name atakr ii and is indicated for interruption of accessory atrioventricular (av) conduction pathways associated with tachycardia, treatment of av nodal re-entrant tachycardia, and creation of complete av block in patients with a difficult to control ventricular response to an atrial arrhythmia.